These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 7588234)
1. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Howe SR; Gottardis MM; Everitt JI; Walker C Endocrinology; 1995 Nov; 136(11):4996-5003. PubMed ID: 7588234 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Fuchs-Young R; Howe S; Hale L; Miles R; Walker C Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075 [TBL] [Abstract][Full Text] [Related]
3. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen. Howe SR; Pass HI; Ethier SP; Matthews WJ; Walker C Cancer Res; 1996 Sep; 56(17):4049-55. PubMed ID: 8752178 [TBL] [Abstract][Full Text] [Related]
4. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025 [TBL] [Abstract][Full Text] [Related]
6. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Osborne CK; Hobbs K; Clark GM Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234 [TBL] [Abstract][Full Text] [Related]
8. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Gottardis MM; Ricchio ME; Satyaswaroop PG; Jordan VC Cancer Res; 1990 Jun; 50(11):3189-92. PubMed ID: 2334915 [TBL] [Abstract][Full Text] [Related]
9. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017 [TBL] [Abstract][Full Text] [Related]
10. Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis. Howe SR; Everitt JI; Gottardis MM; Walker C Ann N Y Acad Sci; 1995 Jun; 761():373-5. PubMed ID: 7625739 [No Abstract] [Full Text] [Related]
11. Autocrine regulation of cell proliferation by estradiol and hydroxytamoxifen of transformed mouse Leydig cells in serum-free culture. Nishizawa Y; Sato B; Miyashita Y; Tsukada S; Hirose T; Kishimoto S; Matsumoto K Endocrinology; 1988 Jan; 122(1):227-35. PubMed ID: 3275537 [TBL] [Abstract][Full Text] [Related]
12. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Long BJ; Jelovac D; Thiantanawat A; Brodie AM Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443 [TBL] [Abstract][Full Text] [Related]
13. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645 [TBL] [Abstract][Full Text] [Related]
14. Functional and growth properties of a myometrial cell line derived from transgenic mice: effects of estradiol and antiestrogens. Blin C; L'Horset F; Romagnolo B; Colnot S; Lambert M; Thomasset M; Kahn A; Vandewalle A; Perret C Endocrinology; 1996 Jun; 137(6):2246-53. PubMed ID: 8641172 [TBL] [Abstract][Full Text] [Related]
15. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976 [TBL] [Abstract][Full Text] [Related]
16. Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus. Campen CA; Jordan VC; Gorski J Endocrinology; 1985 Jun; 116(6):2327-36. PubMed ID: 3996316 [TBL] [Abstract][Full Text] [Related]
17. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Anzai Y; Holinka CF; Kuramoto H; Gurpide E Cancer Res; 1989 May; 49(9):2362-5. PubMed ID: 2706624 [TBL] [Abstract][Full Text] [Related]
18. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Brünner N; Bronzert D; Vindeløv LL; Rygaard K; Spang-Thomsen M; Lippman ME Cancer Res; 1989 Mar; 49(6):1515-20. PubMed ID: 2924304 [TBL] [Abstract][Full Text] [Related]